Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes.
Jerums
G
G
Cooper
M E
ME
Gilbert
R E
RE
Atkins
R C
RC
D000804:Angiotensin II; D057911:Angiotensin Receptor Antagonists; D001713:Biphenyl Compounds / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003928:Diabetic Nephropathies / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D006977:Hypertension, Renal / Q000209:etiology / Q000517:prevention & control*; D000077405:Irbesartan; D007668:Kidney / Q000187:drug effects; D019808:Losartan / Q000008:administration & dosage*; D008297:Male; D011322:Primary Prevention / Q000379:methods; D011379:Prognosis; D013777:Tetrazoles / Q000008:administration & dosage*; D016896:Treatment Outcome
D057911:Angiotensin Receptor Antagonists; D001713:Biphenyl Compounds; D013777:Tetrazoles; D000804:Angiotensin II; D000077405:Irbesartan; D019808:Losartan